SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF), a U.S.-based not-for profit medical research foundation focused on accelerating the rate of target identification and validation to speed drug discovery and development, has launched a first-of-a-kind Drug Discovery Advisory Group (DDAG). MRF’s DDAG is tasked with assessing and prioritizing the organization’s myelin repair therapeutic targets and advising the MRF scientific team on the development of industry-competitive data packages. DDAG members include Stephen Freedman, Ph.D., Mike Gresser, Ph.D., Christopher Lipinski, Ph.D., Bruce McCarthy, M.D., M.B.A., Michael A. Pleiss, Ph.D. and Mark Scheideler Ph.D. DDAG members met with MRF’s Principal Investigators for the first time at a MRF research planning meeting in California in mid-January.
